Hypertrophic effect of inhaled beta2-agonist with and without concurrent exercise training: A randomized controlled trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Hypertrophic effect of inhaled beta2-agonist with and without concurrent exercise training : A randomized controlled trial. / Jessen, Søren; Onslev, Johan; Lemminger, Anders Krogh; Backer, Vibeke; Bangsbo, Jens; Hostrup, Morten.

I: Scandinavian Journal of Medicine & Science in Sports, Bind 28, Nr. 10, 2018, s. 2114-2122.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Jessen, S, Onslev, J, Lemminger, AK, Backer, V, Bangsbo, J & Hostrup, M 2018, 'Hypertrophic effect of inhaled beta2-agonist with and without concurrent exercise training: A randomized controlled trial', Scandinavian Journal of Medicine & Science in Sports, bind 28, nr. 10, s. 2114-2122. https://doi.org/10.1111/sms.13221

APA

Jessen, S., Onslev, J., Lemminger, A. K., Backer, V., Bangsbo, J., & Hostrup, M. (2018). Hypertrophic effect of inhaled beta2-agonist with and without concurrent exercise training: A randomized controlled trial. Scandinavian Journal of Medicine & Science in Sports, 28(10), 2114-2122. https://doi.org/10.1111/sms.13221

Vancouver

Jessen S, Onslev J, Lemminger AK, Backer V, Bangsbo J, Hostrup M. Hypertrophic effect of inhaled beta2-agonist with and without concurrent exercise training: A randomized controlled trial. Scandinavian Journal of Medicine & Science in Sports. 2018;28(10):2114-2122. https://doi.org/10.1111/sms.13221

Author

Jessen, Søren ; Onslev, Johan ; Lemminger, Anders Krogh ; Backer, Vibeke ; Bangsbo, Jens ; Hostrup, Morten. / Hypertrophic effect of inhaled beta2-agonist with and without concurrent exercise training : A randomized controlled trial. I: Scandinavian Journal of Medicine & Science in Sports. 2018 ; Bind 28, Nr. 10. s. 2114-2122.

Bibtex

@article{7a7eb436f5284246ad953614be9396dd,
title = "Hypertrophic effect of inhaled beta2-agonist with and without concurrent exercise training: A randomized controlled trial",
abstract = "Due to a high prevalence of asthma and exercise‐induced bronchoconstriction in elite athletes, there is a high use of beta2‐adrenoceptor agonists (beta2‐agonists) in the athletic population. While anabolic in rodents, no study has been able to detect hypertrophy in humans after chronic beta2‐agonist inhalation. We investigated whether inhaled beta2‐agonist, terbutaline, alters body composition and metabolic rate with and without concurrent exercise training in healthy young men. Sixty‐seven participants completed a 4‐week intervention of daily terbutaline (8 × 0.5 mg) or placebo treatment without concurrent training (habitual; n = 23), with resistance (n = 23) or endurance (n = 21) training 3 times weekly. Before and after the interventions, participant's body composition was determined by dual‐energy X‐ray absorptiometry and resting metabolic rate and substrate oxidation by indirect calorimetry. Terbutaline increased lean body mass by 1.03 kg (95% CI 0.29‐1.76; P < .05) and 1.04 kg (95% CI 0.16‐1.93; P < .05) compared to placebo in the habitual and resistance training group, respectively, but had no effect compared to placebo in the endurance training group [−0.56 kg (95% CI −1.74‐0.62; P > .05)]. Fat mass, bone mineral content, and resting metabolic rate did not change differently between treatments with the intervention. Daily inhalation of terbutaline in near‐therapeutic doses induces skeletal muscle growth. This observation should be a concern for antidoping authorities. ",
keywords = "Faculty of Science, Physical activity, Beta-agonist, Adrenergic, Athletes, Doping",
author = "S{\o}ren Jessen and Johan Onslev and Lemminger, {Anders Krogh} and Vibeke Backer and Jens Bangsbo and Morten Hostrup",
note = "CURIS 2018 NEXS 193",
year = "2018",
doi = "10.1111/sms.13221",
language = "English",
volume = "28",
pages = "2114--2122",
journal = "Scandinavian Journal of Medicine & Science in Sports",
issn = "0905-7188",
publisher = "Wiley-Blackwell",
number = "10",

}

RIS

TY - JOUR

T1 - Hypertrophic effect of inhaled beta2-agonist with and without concurrent exercise training

T2 - A randomized controlled trial

AU - Jessen, Søren

AU - Onslev, Johan

AU - Lemminger, Anders Krogh

AU - Backer, Vibeke

AU - Bangsbo, Jens

AU - Hostrup, Morten

N1 - CURIS 2018 NEXS 193

PY - 2018

Y1 - 2018

N2 - Due to a high prevalence of asthma and exercise‐induced bronchoconstriction in elite athletes, there is a high use of beta2‐adrenoceptor agonists (beta2‐agonists) in the athletic population. While anabolic in rodents, no study has been able to detect hypertrophy in humans after chronic beta2‐agonist inhalation. We investigated whether inhaled beta2‐agonist, terbutaline, alters body composition and metabolic rate with and without concurrent exercise training in healthy young men. Sixty‐seven participants completed a 4‐week intervention of daily terbutaline (8 × 0.5 mg) or placebo treatment without concurrent training (habitual; n = 23), with resistance (n = 23) or endurance (n = 21) training 3 times weekly. Before and after the interventions, participant's body composition was determined by dual‐energy X‐ray absorptiometry and resting metabolic rate and substrate oxidation by indirect calorimetry. Terbutaline increased lean body mass by 1.03 kg (95% CI 0.29‐1.76; P < .05) and 1.04 kg (95% CI 0.16‐1.93; P < .05) compared to placebo in the habitual and resistance training group, respectively, but had no effect compared to placebo in the endurance training group [−0.56 kg (95% CI −1.74‐0.62; P > .05)]. Fat mass, bone mineral content, and resting metabolic rate did not change differently between treatments with the intervention. Daily inhalation of terbutaline in near‐therapeutic doses induces skeletal muscle growth. This observation should be a concern for antidoping authorities.

AB - Due to a high prevalence of asthma and exercise‐induced bronchoconstriction in elite athletes, there is a high use of beta2‐adrenoceptor agonists (beta2‐agonists) in the athletic population. While anabolic in rodents, no study has been able to detect hypertrophy in humans after chronic beta2‐agonist inhalation. We investigated whether inhaled beta2‐agonist, terbutaline, alters body composition and metabolic rate with and without concurrent exercise training in healthy young men. Sixty‐seven participants completed a 4‐week intervention of daily terbutaline (8 × 0.5 mg) or placebo treatment without concurrent training (habitual; n = 23), with resistance (n = 23) or endurance (n = 21) training 3 times weekly. Before and after the interventions, participant's body composition was determined by dual‐energy X‐ray absorptiometry and resting metabolic rate and substrate oxidation by indirect calorimetry. Terbutaline increased lean body mass by 1.03 kg (95% CI 0.29‐1.76; P < .05) and 1.04 kg (95% CI 0.16‐1.93; P < .05) compared to placebo in the habitual and resistance training group, respectively, but had no effect compared to placebo in the endurance training group [−0.56 kg (95% CI −1.74‐0.62; P > .05)]. Fat mass, bone mineral content, and resting metabolic rate did not change differently between treatments with the intervention. Daily inhalation of terbutaline in near‐therapeutic doses induces skeletal muscle growth. This observation should be a concern for antidoping authorities.

KW - Faculty of Science

KW - Physical activity

KW - Beta-agonist

KW - Adrenergic

KW - Athletes

KW - Doping

U2 - 10.1111/sms.13221

DO - 10.1111/sms.13221

M3 - Journal article

C2 - 29777633

VL - 28

SP - 2114

EP - 2122

JO - Scandinavian Journal of Medicine & Science in Sports

JF - Scandinavian Journal of Medicine & Science in Sports

SN - 0905-7188

IS - 10

ER -

ID: 196713436